UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation

Journal of controlled release, 2015-01, Vol.197, p.29-40

2015

Volltextzugriff (PDF)

Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity

Journal of medicinal chemistry, 2020-04, Vol.63 (7), p.3508-3521

2020

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria

Journal of medicinal chemistry, 2019-03, Vol.62 (6), p.2950-2973

2019

Volltextzugriff (PDF)

Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug

Bioconjugate chemistry, 2015-12, Vol.26 (12), p.2397-2407

2015

Volltextzugriff (PDF)

Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization

Journal of medicinal chemistry, 2014-11, Vol.57 (21), p.9078-9095

2014

Volltextzugriff (PDF)

Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B

Bioorganic chemistry, 2020-03, Vol.96, p.103656, Article 103656

2020

Volltextzugriff (PDF)

Drug Design Targeting T‑Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer

Journal of medicinal chemistry, 2019-11, Vol.62 (22), p.10182-10203

2019

Volltextzugriff (PDF)

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases

Bioorganic & medicinal chemistry letters, 2016-05, Vol.26 (10), p.2464-2469

2016

Volltextzugriff (PDF)

Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice

Scientific reports, 2016-08, Vol.6 (1), p.32062, Article 32062

2016

Volltextzugriff (PDF)

A Phase I, Single‐Ascending‐Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS‐2969b, a Novel GyrB Inhibitor

Journal of clinical pharmacology, 2018-12, Vol.58 (12), p.1557-1565

2018

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (24), p.6598-6603

2013

Volltextzugriff (PDF)

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

Clinical cancer research, 2015-12, Vol.21 (23), p.5314-5323

2015

Volltextzugriff (PDF)

Novel N‑Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis

Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4889-4905

2014

Volltextzugriff (PDF)

Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches

Journal of biomolecular structure & dynamics, 2020-02, Vol.38 (3), p.791-806

2020

Volltextzugriff (PDF)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

Investigational new drugs, 2019-08, Vol.37 (4), p.693-701

2019

Volltextzugriff (PDF)

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases

Bioorganic & medicinal chemistry letters, 2011-12, Vol.21 (24), p.7483-7488

2011

Volltextzugriff (PDF)

A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics

Investigative ophthalmology & visual science, 2015-04, Vol.56 (4), p.2755-2763

2015

Volltextzugriff (PDF)

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Investigational new drugs, 2017-08, Vol.35 (4), p.478-490

2017

Volltextzugriff (PDF)

Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux

ACS chemical biology, 2019-06, Vol.14 (6), p.1110-1114

2019

Volltextzugriff (PDF)

Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats

Antimicrobial agents and chemotherapy, 2014-11, Vol.58 (11), p.6477-6483

2014

Volltextzugriff (PDF)

Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma

Journal of labelled compounds & radiopharmaceuticals, 2016-02, Vol.59 (2), p.72-77

2016

Volltextzugriff (PDF)

Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles

Drug delivery and translational research, 2017-02, Vol.7 (1), p.27-36

2017

Volltextzugriff (PDF)

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

Expert opinion on pharmacotherapy, 2013-07, Vol.14 (10), p.1417-1427

2013

Volltextzugriff (PDF)

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers

Journal of clinical pharmacology, 2014-07, Vol.54 (7), p.765-775

2014

Volltextzugriff (PDF)

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.549-564

2013

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(169)

Publikationsform

Artikel
(204)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(177)
Life Sciences & Biomedicine
(171)
Humans
(152)
Topoisomerase Ii Inhibitors
(105)
Pharmacology & Pharmacy
(95)
Animals
(93)
Oncology
(71)
Biological And Medical Sciences
(70)
Medical Sciences
(70)
Female
(66)
Pharmacology. Drug Treatments
(65)
Male
(63)
Antineoplastic Agents - Pharmacokinetics
(57)
Mice
(53)
Antineoplastic Agents
(51)
Pharmacokinetics
(46)
Antineoplastic Agents - Pharmacology
(38)
Adult
(37)
Dna Topoisomerases, Type Ii - Metabolism
(37)
Middle Aged
(37)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation

Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity

Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria

Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug

Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization

Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B

Drug Design Targeting T‑Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases

Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice

A Phase I, Single‐Ascending‐Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS‐2969b, a Novel GyrB Inhibitor

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

Novel N‑Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis

Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases

A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux

Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats

Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma

Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

Suchergebnisse filtern